GH-Tech(SZ:000004) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2026-01-28 23:11Group 1 - The company held its first extraordinary board meeting of 2026 on January 28, 2026, with all five directors present, and the meeting complied with relevant laws and regulations [2][3][24] - The board approved a financial assistance proposal where the company and an affiliate, Hainan Zhijian Pharmaceutical Co., Ltd., will provide a total of up to RMB 120 million to its subsidiary, Zhongshan Runle Pharmaceutical Co., Ltd., with the company contributing up to RMB 40 million [12][13][14] - The financial assistance is intended to support Zhongshan Runle's working capital needs and debt repayment, with a loan term of two years at an interest rate of 3% [12][13][20] Group 2 - The board's decision on the financial assistance will be submitted to the shareholders' meeting for approval, with related parties abstaining from voting [5][25][34] - The company has not previously provided financial assistance to Zhongshan Runle, and the total financial assistance balance before this announcement was zero [19][26] - The independent directors reviewed and approved the financial assistance proposal, stating it aligns with Zhongshan Runle's operational needs and does not adversely affect the company's normal operations [23][24] Group 3 - The company will hold its first extraordinary shareholders' meeting on February 13, 2026, to discuss the approved financial assistance proposal [30][31][34] - The meeting will allow for both on-site and online voting, with specific timeframes for participation [31][37] - Shareholders must register by February 6, 2026, to attend the meeting, and the meeting will take place at the company's headquarters [33][36]